Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3082-3096
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3082
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3082
Table 1 Association between BCAR3 expression and the clinical parameters in patients with hepatocellular carcinoma in The Cancer Genome Altas, n (%)
| Characteristics | Low expression of BCAR3 | High expression of BCAR3 | P value |
| n | 187 | 187 | |
| Gender | 0.912 | ||
| Male | 127 (34) | 126 (33.7) | |
| Female | 60 (16) | 61 (16.3) | |
| Age | 0.275 | ||
| ≤ 60 | 94 (25.2) | 83 (22.3) | |
| > 60 | 93 (24.9) | 103 (27.6) | |
| Tumor status | 0.014 | ||
| Tumor free | 111 (31.3) | 91 (25.6) | |
| With tumor | 64 (18) | 89 (25.1) | |
| Pathologic T stage | 0.085 | ||
| T1 and T2 | 146 (39.4) | 132 (35.6) | |
| T3 | 37 (10) | 43 (11.6) | |
| T4 | 3 (0.8) | 10 (2.7) | |
| Pathologic M stage | 0.667 | ||
| M0 | 138 (50.7) | 130 (47.8) | |
| M1 | 3 (1.1) | 1 (0.4) | |
| AFP (ng/mL) | 0.056 | ||
| ≤ 400 | 110 (39.3) | 105 (37.5) | |
| > 400 | 42 (15) | 23 (8.2) | |
| Histological type | 0.996 | ||
| Fibrolamellar carcinoma | 1 (0.3) | 2 (0.5) | |
| Hepatocellular carcinoma | 183 (49.9) | 181 (49.3) | |
| Overall survival event | 0.017 | ||
| Alive | 133 (35.6) | 111 (29.7) | |
| Dead | 54 (14.4) | 76 (20.3) | |
| Disease specific survival event | 0.009 | ||
| No | 153 (41.8) | 134 (36.6) | |
| Yes | 29 (7.9) | 50 (13.7) | |
| Progression free interval event | 0.005 | ||
| No | 109 (29.1) | 82 (21.9) | |
| Yes | 78 (20.9) | 105 (28.1) |
- Citation: Shi HQ, Huang S, Ma XY, Tan ZJ, Luo R, Luo B, Zhang W, Shi L, Zhong XL, Lü MH, Chen X, Tang XW. BCAR3 and BCAR3-related competing endogenous RNA expression in hepatocellular carcinoma and their prognostic value. World J Gastrointest Oncol 2024; 16(7): 3082-3096
- URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3082.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3082